Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2009

View Archived Issues

Novel mutilin derivatives with antibacterial activity reported in recent Kyorin patent

Mpex Pharmaceuticals patent discloses novel bacterial efflux pump inhibitors

New angiotensin II AT1 receptor antagonists developed by Eldrug researchers

GSK and Archemix form strategic alliance to develop aptamers for inflammatory diseases

VIA licenses drug candidates from Roche for metabolic disease

GenVec reports on developments in malaria vaccine program

Clinical data on pralatrexate in lymphomas presented at ASH annual meeting

Phase II studies assess single-agent dasatinib in breast cancer

FDA advises NMRC not to initiate clinical trial of Biopure's Hemopure

IGF-1 does not affect outcome measures in phase III amyotrophic lateral sclerosis trial

Vinflunine with trastuzumab active as first-line treatment in metastatic breast cancer

Acura and King Pharmaceuticals submit NDA to FDA for Acurox anti-abuse opioid analgesic

EMEA accepts Schering's corifollitropin alfa submission for review

FDA's Cardio Renal Advisory Committee to review prasugrel

King provides update on Embeda NDA review

Pfizer exercises commercial license agreement for novel vaccines with Cytos

FDA approves once-daily Ryzolt for moderate to moderately severe pain

Galapagos selects preclinical candidate, G-100192, for cachexia program

Alnylam files IND application with FDA to initiate phase I human clinical trial of ALN-VSP

Roche purchases shares in tender offer for Memory Pharmaceuticals

Death of Chinese minor not related to Sinovac's hepatitis A vaccine Healive

Valeant Pharmaceuticals International completes acquisition of Dow Pharmaceutical Sciences

Lodotra recommended for European regulatory approval

MedImmune submits MAA in European Union for intranasal influenza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...